Sensei Biotherapeutics Inc
SNSE
Get informed when a big investor buys or sells
+ FollowMarket Cap$18.59M
Close$
$5.68
59% downside
Current Fair Value
59% downsideOvervalued by 59% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $18.59 Million |
|---|---|
| Enterprise Value | $-7,725,117.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-16.72 |
| Beta | -0.23 |
| Outstanding Shares | 5,643,222 |
Return
| Return on Equity | -113.05% |
|---|---|
| Return on Assets | -103.29% |
| Return on Invested Capital | -109.17% |
Valuation & Multiples
| P/E Ratio | -0.23 |
|---|---|
| PEG | -0.1 |
| Price to Sales | - |
| Price to Book Ratio | 0.45 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | 0.04 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | -0.08 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 4, 2026
EPS Estimate
$-5.04
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 194.39%▲ 190.56% |
|---|---|
| Total Invested | $79.35M▲ 15314.44% |
| Investors Holding | 31▲ 21.00% |
ESG Score
No data
About Sensei Biotherapeutics Inc
31 employeesSensei Biotherapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and delivery of next generation immunotherapies for the treatment of cancer and infectious diseases. The company has developed a p...